Codexis, Inc.
NASDAQ:CDXSBiotechnology
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
Volume 1.47M
Average 1.15M
CDXS EBITDA Margin
EBITDA as a percentage of revenue.
Codexis, Inc.NASDAQ: CDXS
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -42.3%
EBITDA Margin was -42.3% in Q1 FY2026, up 194.0 pp from a year earlier. On a trailing-twelve-month basis it was -28.2%, up 91.2 pp year over year. Over 3 fiscal years it narrowed by 29.1 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -35.0% for the fiscal year ending Dec 2026, up from -48.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -42.3%-72.7 pp QoQ
- Last fiscal yearDec 2025
- -48.1%+41.9 pp YoY
- LTMMar 2026
- -28.2%+91.2 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -48.1%
- Year-over-year change
- +41.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -48.1% | +41.9pp |
| FY2024 | 2024-12-31 | -90.0% | -19.7pp |
| FY2023 | 2023-12-31 | -70.3% | -51.3pp |
| FY2022 | 2022-12-31 | -19.0% | -4.5pp |
| FY2021 | 2021-12-31 | -14.5% | — |
EBITDA Margin vs competitors
How CDXS compares with its peers on the latest reported figures
- CDXS's LTM Mar 2026 EBITDA Margin of -28.2% is the highest of the 9 companies compared; the peer median is -696.6%.
- Its year-over-year change of +91.2 pp is the 3rd highest of 9, against a peer median of -136.8 pp.
- Over three fiscal years its change of -29.1 pp compares with a peer median of -178.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -28.2% | +91.2 pp | -29.1 pp | |
| LTM Mar 2026 | -117.0% | +50.4 pp | -225.4 pp | |
| LTM Mar 2026 | -135.5% | +244.4 pp | — | |
| LTM Mar 2026 | -287.9% | -44.6 pp | +113.4 pp | |
| LTM Mar 2026 | -339.9% | -229.0 pp | -131.5 pp | |
| LTM Mar 2026 | -1053.3% | +3016.0 pp | — | |
| FY2025 | -1566.1% | -1194.4 pp | -1544.8 pp | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -2329.5% | -862.2 pp | +207.6 pp |
| LTM Mar 2026 | -8872.8% | -9159.7 pp | -2521.0 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding CDXS) | -696.6% | -136.8 pp | -178.5 pp | |
Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 104.75M | 138.59M | 70.14M | 59.35M | 70.39M |
| Cost of Revenue | 22.21M | 38.03M | 12.81M | 16.29M | 9.34M |
| Gross Profit | 82.55M | 100.56M | 57.33M | 43.06M | 61.05M |
| Gross Margin | 78.8% | 72.6% | 81.7% | 72.6% | 86.7% |
| Research & Development | 55.92M | 80.1M | 58.89M | 46.26M | 52.31M |
| Selling, General & Admin | 49.32M | 52.17M | 53.25M | 55.15M | 47.07M |
| Operating Expenses | 105.24M | 135.44M | 125.4M | 101.58M | 99.38M |
| Depreciation & Amortization | 5.95M | 5.4M | 5.52M | 4.95M | 5.25M |
| EBITDA | (15.14M) | (26.31M) | (49.28M) | (53.41M) | (33.87M) |
| EBITDA Margin | -14.5% | -19.0% | -70.3% | -90.0% | -48.1% |
| Operating Income | (22.7M) | (34.88M) | (68.07M) | (58.52M) | (38.33M) |
| Operating Margin | -21.7% | -25.2% | -97.0% | -98.6% | -54.5% |
| Interest Income | 459K | 1.44M | 4.17M | 3.67M | 2.63M |
| Interest Expense | 0 | 0 | 0 | 0 | 4.81M |
| Other Income / Expenses | 1.61M | 1.57M | (8.1M) | (6.72M) | (5.6M) |
| Income Before Tax | (21.09M) | (33.32M) | (76.17M) | (65.24M) | (43.93M) |
| Pre-Tax Margin | -20.1% | -24.0% | -108.6% | -109.9% | -62.4% |
| Income Tax Expense | 189K | 276K | 69K | 34K | 47K |
| Net Income | (21.28M) | (33.59M) | (76.24M) | (65.28M) | (43.97M) |
| Net Margin | -20.3% | -24.2% | -108.7% | -110.0% | -62.5% |
| EPS (Basic) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| EPS (Diluted) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| Weighted Avg Shares | 64.57M | 65.34M | 68.13M | 73.41M | 87.14M |
| Weighted Avg Shares (Diluted) | 64.57M | 65.34M | 68.13M | 73.41M | 87.14M |
Codexis, Inc.
NASDAQ:CDXS
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.